BTIG analyst Kaveri Pohlman maintained a Buy rating on Sonnet BioTherapeutics Holdings (SONN – Research Report) on January 5 and set a price target of $2.00. The company’s shares closed last Friday at $1.53.
Pohlman covers the Healthcare sector, focusing on stocks such as Arcus Biosciences, Genmab, and BioAtla. According to TipRanks, Pohlman has an average return of -6.5% and a 33.82% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sonnet BioTherapeutics Holdings with a $4.50 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Sonnet BioTherapeutics Holdings’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $3.68 million. In comparison, last year the company earned a revenue of $12.81 thousand and had a GAAP net loss of $7.44 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sonnet BioTherapeutics Holdings (SONN) Company Description:
Sonnet BioTherapeutics (NASDAQ:SONN) is a clinical-stage biotechnology company that is focused on the development of drugs for the treatment of cancer.
Read More on SONN:
